nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ALB—atherosclerosis	0.226	1	CbGaD
Canagliflozin—ABCC2—Ezetimibe—atherosclerosis	0.0869	0.153	CbGbCtD
Canagliflozin—ABCC2—Simvastatin—atherosclerosis	0.0808	0.143	CbGbCtD
Canagliflozin—ABCC2—Pravastatin—atherosclerosis	0.0791	0.14	CbGbCtD
Canagliflozin—ABCC2—Lovastatin—atherosclerosis	0.0791	0.14	CbGbCtD
Canagliflozin—ALB—Rosuvastatin—atherosclerosis	0.0542	0.0956	CbGbCtD
Canagliflozin—ABCB1—Ezetimibe—atherosclerosis	0.0283	0.05	CbGbCtD
Canagliflozin—ABCB1—Simvastatin—atherosclerosis	0.0263	0.0465	CbGbCtD
Canagliflozin—ABCB1—Pravastatin—atherosclerosis	0.0258	0.0455	CbGbCtD
Canagliflozin—ABCB1—Lovastatin—atherosclerosis	0.0258	0.0455	CbGbCtD
Canagliflozin—CYP3A4—Ezetimibe—atherosclerosis	0.017	0.03	CbGbCtD
Canagliflozin—CYP3A4—Rosuvastatin—atherosclerosis	0.017	0.03	CbGbCtD
Canagliflozin—CYP3A4—Simvastatin—atherosclerosis	0.0158	0.0278	CbGbCtD
Canagliflozin—CYP3A4—Pravastatin—atherosclerosis	0.0154	0.0272	CbGbCtD
Canagliflozin—CYP3A4—Lovastatin—atherosclerosis	0.0154	0.0272	CbGbCtD
Canagliflozin—Dyslipidaemia—Pravastatin—atherosclerosis	0.00811	0.0907	CcSEcCtD
Canagliflozin—High density lipoprotein decreased—Niacin—atherosclerosis	0.00635	0.071	CcSEcCtD
Canagliflozin—Rash pustular—Niacin—atherosclerosis	0.0016	0.0179	CcSEcCtD
Canagliflozin—Diabetes mellitus—Rosuvastatin—atherosclerosis	0.00146	0.0163	CcSEcCtD
Canagliflozin—Renal failure acute—Rosuvastatin—atherosclerosis	0.00138	0.0154	CcSEcCtD
Canagliflozin—Nocturia—Pravastatin—atherosclerosis	0.00135	0.0151	CcSEcCtD
Canagliflozin—Photosensitivity—Lovastatin—atherosclerosis	0.00123	0.0137	CcSEcCtD
Canagliflozin—Vaginal infection—Niacin—atherosclerosis	0.0012	0.0135	CcSEcCtD
Canagliflozin—Photosensitivity—Ezetimibe—atherosclerosis	0.0012	0.0135	CcSEcCtD
Canagliflozin—Rash maculo-papular—Niacin—atherosclerosis	0.00116	0.013	CcSEcCtD
Canagliflozin—Diabetes mellitus—Simvastatin—atherosclerosis	0.00116	0.013	CcSEcCtD
Canagliflozin—Urine output increased—Niacin—atherosclerosis	0.00115	0.0129	CcSEcCtD
Canagliflozin—Breast disorder—Rosuvastatin—atherosclerosis	0.00115	0.0128	CcSEcCtD
Canagliflozin—Photosensitivity—Simvastatin—atherosclerosis	0.00115	0.0128	CcSEcCtD
Canagliflozin—Pancreatitis—Rosuvastatin—atherosclerosis	0.00108	0.012	CcSEcCtD
Canagliflozin—Diabetes mellitus—Niacin—atherosclerosis	0.00106	0.0119	CcSEcCtD
Canagliflozin—Polyuria—Niacin—atherosclerosis	0.00105	0.0118	CcSEcCtD
Canagliflozin—Photosensitivity—Pravastatin—atherosclerosis	0.00104	0.0116	CcSEcCtD
Canagliflozin—Renal failure acute—Pravastatin—atherosclerosis	0.000987	0.011	CcSEcCtD
Canagliflozin—Breast disorder—Ezetimibe—atherosclerosis	0.000955	0.0107	CcSEcCtD
Canagliflozin—Urinary tract infection—Rosuvastatin—atherosclerosis	0.000952	0.0106	CcSEcCtD
Canagliflozin—Pancreatitis—Lovastatin—atherosclerosis	0.000913	0.0102	CcSEcCtD
Canagliflozin—Pancreatitis—Ezetimibe—atherosclerosis	0.000895	0.01	CcSEcCtD
Canagliflozin—Pancreatitis—Simvastatin—atherosclerosis	0.000854	0.00955	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Lovastatin—atherosclerosis	0.00085	0.0095	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Niacin—atherosclerosis	0.000845	0.00945	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Ezetimibe—atherosclerosis	0.000833	0.00932	CcSEcCtD
Canagliflozin—Urinary tract infection—Lovastatin—atherosclerosis	0.000807	0.00902	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Simvastatin—atherosclerosis	0.000795	0.00889	CcSEcCtD
Canagliflozin—Pancreatitis—Pravastatin—atherosclerosis	0.000772	0.00863	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Pravastatin—atherosclerosis	0.000719	0.00804	CcSEcCtD
Canagliflozin—Angioedema—Rosuvastatin—atherosclerosis	0.000699	0.00782	CcSEcCtD
Canagliflozin—Urinary tract infection—Pravastatin—atherosclerosis	0.000682	0.00763	CcSEcCtD
Canagliflozin—Angiopathy—Ezetimibe—atherosclerosis	0.000663	0.00742	CcSEcCtD
Canagliflozin—Malnutrition—Ezetimibe—atherosclerosis	0.000636	0.00712	CcSEcCtD
Canagliflozin—Erythema—Ezetimibe—atherosclerosis	0.000636	0.00712	CcSEcCtD
Canagliflozin—Infection—Rosuvastatin—atherosclerosis	0.000621	0.00694	CcSEcCtD
Canagliflozin—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000613	0.00685	CcSEcCtD
Canagliflozin—Erythema—Simvastatin—atherosclerosis	0.000607	0.00679	CcSEcCtD
Canagliflozin—Angioedema—Lovastatin—atherosclerosis	0.000593	0.00663	CcSEcCtD
Canagliflozin—Angioedema—Ezetimibe—atherosclerosis	0.000581	0.0065	CcSEcCtD
Canagliflozin—Angiopathy—Niacin—atherosclerosis	0.000581	0.00649	CcSEcCtD
Canagliflozin—Malnutrition—Niacin—atherosclerosis	0.000557	0.00623	CcSEcCtD
Canagliflozin—Erythema—Niacin—atherosclerosis	0.000557	0.00623	CcSEcCtD
Canagliflozin—Angioedema—Simvastatin—atherosclerosis	0.000554	0.0062	CcSEcCtD
Canagliflozin—Dry mouth—Lovastatin—atherosclerosis	0.00054	0.00604	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000538	0.00602	CcSEcCtD
Canagliflozin—Constipation—Rosuvastatin—atherosclerosis	0.000534	0.00597	CcSEcCtD
Canagliflozin—Dry mouth—Ezetimibe—atherosclerosis	0.00053	0.00592	CcSEcCtD
Canagliflozin—Infection—Lovastatin—atherosclerosis	0.000526	0.00588	CcSEcCtD
Canagliflozin—Infection—Ezetimibe—atherosclerosis	0.000516	0.00577	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000511	0.00571	CcSEcCtD
Canagliflozin—Nervous system disorder—Ezetimibe—atherosclerosis	0.000509	0.0057	CcSEcCtD
Canagliflozin—Angioedema—Niacin—atherosclerosis	0.000509	0.00569	CcSEcCtD
Canagliflozin—Skin disorder—Ezetimibe—atherosclerosis	0.000504	0.00564	CcSEcCtD
Canagliflozin—Angioedema—Pravastatin—atherosclerosis	0.000501	0.00561	CcSEcCtD
Canagliflozin—Syncope—Niacin—atherosclerosis	0.0005	0.00559	CcSEcCtD
Canagliflozin—Urticaria—Rosuvastatin—atherosclerosis	0.000496	0.00555	CcSEcCtD
Canagliflozin—Abdominal pain—Rosuvastatin—atherosclerosis	0.000494	0.00552	CcSEcCtD
Canagliflozin—Infection—Simvastatin—atherosclerosis	0.000492	0.0055	CcSEcCtD
Canagliflozin—Loss of consciousness—Niacin—atherosclerosis	0.00049	0.00548	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000471	0.00527	CcSEcCtD
Canagliflozin—Dry mouth—Niacin—atherosclerosis	0.000464	0.00519	CcSEcCtD
Canagliflozin—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00046	0.00515	CcSEcCtD
Canagliflozin—Fatigue—Lovastatin—atherosclerosis	0.000456	0.0051	CcSEcCtD
Canagliflozin—Constipation—Lovastatin—atherosclerosis	0.000453	0.00506	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000448	0.00501	CcSEcCtD
Canagliflozin—Asthenia—Rosuvastatin—atherosclerosis	0.000448	0.00501	CcSEcCtD
Canagliflozin—Fatigue—Ezetimibe—atherosclerosis	0.000448	0.00501	CcSEcCtD
Canagliflozin—Shock—Niacin—atherosclerosis	0.000447	0.005	CcSEcCtD
Canagliflozin—Infection—Pravastatin—atherosclerosis	0.000445	0.00497	CcSEcCtD
Canagliflozin—Constipation—Ezetimibe—atherosclerosis	0.000444	0.00497	CcSEcCtD
Canagliflozin—Pruritus—Rosuvastatin—atherosclerosis	0.000442	0.00494	CcSEcCtD
Canagliflozin—Skin disorder—Niacin—atherosclerosis	0.000442	0.00494	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000433	0.00484	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000427	0.00478	CcSEcCtD
Canagliflozin—Fatigue—Simvastatin—atherosclerosis	0.000427	0.00477	CcSEcCtD
Canagliflozin—Hypotension—Niacin—atherosclerosis	0.000425	0.00475	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000425	0.00475	CcSEcCtD
Canagliflozin—Constipation—Simvastatin—atherosclerosis	0.000423	0.00474	CcSEcCtD
Canagliflozin—Urticaria—Lovastatin—atherosclerosis	0.000421	0.0047	CcSEcCtD
Canagliflozin—Abdominal pain—Lovastatin—atherosclerosis	0.000418	0.00468	CcSEcCtD
Canagliflozin—Dizziness—Rosuvastatin—atherosclerosis	0.000413	0.00462	CcSEcCtD
Canagliflozin—Urticaria—Ezetimibe—atherosclerosis	0.000412	0.00461	CcSEcCtD
Canagliflozin—Abdominal pain—Ezetimibe—atherosclerosis	0.00041	0.00459	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000405	0.00453	CcSEcCtD
Canagliflozin—Rash—Rosuvastatin—atherosclerosis	0.000394	0.00441	CcSEcCtD
Canagliflozin—Dermatitis—Rosuvastatin—atherosclerosis	0.000393	0.0044	CcSEcCtD
Canagliflozin—Urticaria—Simvastatin—atherosclerosis	0.000393	0.0044	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Niacin—atherosclerosis	0.000393	0.00439	CcSEcCtD
Canagliflozin—Abdominal pain—Simvastatin—atherosclerosis	0.000391	0.00438	CcSEcCtD
Canagliflozin—Hypersensitivity—Lovastatin—atherosclerosis	0.00039	0.00436	CcSEcCtD
Canagliflozin—Fatigue—Pravastatin—atherosclerosis	0.000386	0.00432	CcSEcCtD
Canagliflozin—Constipation—Pravastatin—atherosclerosis	0.000383	0.00428	CcSEcCtD
Canagliflozin—Hypersensitivity—Ezetimibe—atherosclerosis	0.000383	0.00428	CcSEcCtD
Canagliflozin—Asthenia—Lovastatin—atherosclerosis	0.00038	0.00425	CcSEcCtD
Canagliflozin—Pruritus—Lovastatin—atherosclerosis	0.000375	0.00419	CcSEcCtD
Canagliflozin—Asthenia—Ezetimibe—atherosclerosis	0.000373	0.00417	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Niacin—atherosclerosis	0.000372	0.00416	CcSEcCtD
Canagliflozin—Nausea—Rosuvastatin—atherosclerosis	0.000371	0.00415	CcSEcCtD
Canagliflozin—Pruritus—Ezetimibe—atherosclerosis	0.000367	0.00411	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000366	0.00409	CcSEcCtD
Canagliflozin—Hypersensitivity—Simvastatin—atherosclerosis	0.000365	0.00408	CcSEcCtD
Canagliflozin—Urticaria—Niacin—atherosclerosis	0.000361	0.00404	CcSEcCtD
Canagliflozin—Abdominal pain—Niacin—atherosclerosis	0.000359	0.00402	CcSEcCtD
Canagliflozin—Urticaria—Pravastatin—atherosclerosis	0.000356	0.00398	CcSEcCtD
Canagliflozin—Asthenia—Simvastatin—atherosclerosis	0.000355	0.00397	CcSEcCtD
Canagliflozin—Abdominal pain—Pravastatin—atherosclerosis	0.000354	0.00396	CcSEcCtD
Canagliflozin—Pruritus—Simvastatin—atherosclerosis	0.00035	0.00392	CcSEcCtD
Canagliflozin—Dizziness—Lovastatin—atherosclerosis	0.00035	0.00392	CcSEcCtD
Canagliflozin—Dizziness—Ezetimibe—atherosclerosis	0.000343	0.00384	CcSEcCtD
Canagliflozin—Hypersensitivity—Niacin—atherosclerosis	0.000335	0.00375	CcSEcCtD
Canagliflozin—Rash—Lovastatin—atherosclerosis	0.000334	0.00373	CcSEcCtD
Canagliflozin—Dermatitis—Lovastatin—atherosclerosis	0.000333	0.00373	CcSEcCtD
Canagliflozin—Hypersensitivity—Pravastatin—atherosclerosis	0.00033	0.00369	CcSEcCtD
Canagliflozin—Dizziness—Simvastatin—atherosclerosis	0.000327	0.00366	CcSEcCtD
Canagliflozin—Rash—Ezetimibe—atherosclerosis	0.000327	0.00366	CcSEcCtD
Canagliflozin—Dermatitis—Ezetimibe—atherosclerosis	0.000327	0.00366	CcSEcCtD
Canagliflozin—Asthenia—Niacin—atherosclerosis	0.000326	0.00365	CcSEcCtD
Canagliflozin—Pruritus—Niacin—atherosclerosis	0.000322	0.0036	CcSEcCtD
Canagliflozin—Asthenia—Pravastatin—atherosclerosis	0.000321	0.00359	CcSEcCtD
Canagliflozin—Pruritus—Pravastatin—atherosclerosis	0.000317	0.00354	CcSEcCtD
Canagliflozin—Nausea—Lovastatin—atherosclerosis	0.000314	0.00352	CcSEcCtD
Canagliflozin—Rash—Simvastatin—atherosclerosis	0.000312	0.00349	CcSEcCtD
Canagliflozin—Dermatitis—Simvastatin—atherosclerosis	0.000312	0.00349	CcSEcCtD
Canagliflozin—Nausea—Ezetimibe—atherosclerosis	0.000308	0.00345	CcSEcCtD
Canagliflozin—Dizziness—Niacin—atherosclerosis	0.000301	0.00336	CcSEcCtD
Canagliflozin—Dizziness—Pravastatin—atherosclerosis	0.000296	0.00331	CcSEcCtD
Canagliflozin—Nausea—Simvastatin—atherosclerosis	0.000294	0.00329	CcSEcCtD
Canagliflozin—Rash—Niacin—atherosclerosis	0.000287	0.00321	CcSEcCtD
Canagliflozin—Dermatitis—Niacin—atherosclerosis	0.000286	0.0032	CcSEcCtD
Canagliflozin—Rash—Pravastatin—atherosclerosis	0.000282	0.00316	CcSEcCtD
Canagliflozin—Dermatitis—Pravastatin—atherosclerosis	0.000282	0.00315	CcSEcCtD
Canagliflozin—Nausea—Niacin—atherosclerosis	0.00027	0.00302	CcSEcCtD
Canagliflozin—Nausea—Pravastatin—atherosclerosis	0.000266	0.00297	CcSEcCtD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—SCARB1—atherosclerosis	2.56e-05	0.000217	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—ALB—atherosclerosis	2.55e-05	0.000216	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—CETP—atherosclerosis	2.54e-05	0.000216	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—IGF1—atherosclerosis	2.49e-05	0.000212	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—TGFB1—atherosclerosis	2.49e-05	0.000212	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—TGFB1—atherosclerosis	2.49e-05	0.000212	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—APOA1—atherosclerosis	2.48e-05	0.000211	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—atherosclerosis	2.46e-05	0.000208	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	2.44e-05	0.000207	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—NOS3—atherosclerosis	2.44e-05	0.000207	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—GSTM1—atherosclerosis	2.42e-05	0.000205	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—HMGCR—atherosclerosis	2.42e-05	0.000205	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—AKT1—atherosclerosis	2.4e-05	0.000203	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—GSTM1—atherosclerosis	2.39e-05	0.000203	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—NAMPT—atherosclerosis	2.37e-05	0.000201	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—SERPINE1—atherosclerosis	2.37e-05	0.000201	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	2.36e-05	0.0002	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—LIPC—atherosclerosis	2.36e-05	0.0002	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—IL6—atherosclerosis	2.35e-05	0.0002	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—APOC3—atherosclerosis	2.34e-05	0.000199	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—LDLR—atherosclerosis	2.33e-05	0.000198	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CETP—atherosclerosis	2.27e-05	0.000193	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—LTA4H—atherosclerosis	2.27e-05	0.000193	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ABCG8—atherosclerosis	2.27e-05	0.000193	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—KNG1—atherosclerosis	2.27e-05	0.000193	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PLAUR—atherosclerosis	2.25e-05	0.000191	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—PLAT—atherosclerosis	2.24e-05	0.00019	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PTGS2—atherosclerosis	2.23e-05	0.000189	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—CETP—atherosclerosis	2.23e-05	0.000189	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PLG—atherosclerosis	2.2e-05	0.000187	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—SCARB1—atherosclerosis	2.18e-05	0.000185	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—ABCA1—atherosclerosis	2.15e-05	0.000183	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	2.12e-05	0.00018	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SOD1—atherosclerosis	2.11e-05	0.000179	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—HMGCR—atherosclerosis	2.06e-05	0.000174	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ABCG1—atherosclerosis	2.05e-05	0.000174	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—atherosclerosis	2.04e-05	0.000173	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IGF2—atherosclerosis	2e-05	0.00017	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—ALB—atherosclerosis	1.97e-05	0.000167	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—PLAT—atherosclerosis	1.96e-05	0.000167	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—APOB—atherosclerosis	1.94e-05	0.000165	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—LCAT—atherosclerosis	1.93e-05	0.000163	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—FABP4—atherosclerosis	1.93e-05	0.000163	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—PLG—atherosclerosis	1.9e-05	0.000162	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APOA4—atherosclerosis	1.89e-05	0.00016	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—IL6—atherosclerosis	1.88e-05	0.00016	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—IL6—atherosclerosis	1.88e-05	0.00016	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP7A1—atherosclerosis	1.86e-05	0.000158	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	1.85e-05	0.000157	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ABCA1—atherosclerosis	1.83e-05	0.000156	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PRKCG—atherosclerosis	1.81e-05	0.000153	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ABCG1—atherosclerosis	1.8e-05	0.000152	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	1.77e-05	0.00015	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—atherosclerosis	1.77e-05	0.00015	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—CD36—atherosclerosis	1.76e-05	0.00015	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—HMOX1—atherosclerosis	1.76e-05	0.000149	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—atherosclerosis	1.74e-05	0.000147	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—AKT1—atherosclerosis	1.73e-05	0.000147	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—AKT1—atherosclerosis	1.73e-05	0.000147	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP27A1—atherosclerosis	1.72e-05	0.000146	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—LDLRAP1—atherosclerosis	1.72e-05	0.000146	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	1.69e-05	0.000143	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—FABP4—atherosclerosis	1.69e-05	0.000143	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—LCAT—atherosclerosis	1.69e-05	0.000143	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—APOB—atherosclerosis	1.68e-05	0.000143	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—PLG—atherosclerosis	1.67e-05	0.000142	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APOA4—atherosclerosis	1.66e-05	0.000141	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	1.65e-05	0.00014	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—VEGFA—atherosclerosis	1.63e-05	0.000138	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ALOX5AP—atherosclerosis	1.63e-05	0.000138	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ALOX15—atherosclerosis	1.63e-05	0.000138	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APOA2—atherosclerosis	1.63e-05	0.000138	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PLA2G2A—atherosclerosis	1.63e-05	0.000138	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP7A1—atherosclerosis	1.63e-05	0.000138	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PDGFB—atherosclerosis	1.63e-05	0.000138	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PLTP—atherosclerosis	1.61e-05	0.000137	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MMP1—atherosclerosis	1.61e-05	0.000137	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ABCG5—atherosclerosis	1.61e-05	0.000136	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	1.61e-05	0.000136	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—atherosclerosis	1.6e-05	0.000136	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—HMOX1—atherosclerosis	1.57e-05	0.000133	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—LPA—atherosclerosis	1.55e-05	0.000132	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—CAV1—atherosclerosis	1.54e-05	0.000131	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—MAPK3—atherosclerosis	1.54e-05	0.000131	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—HMOX1—atherosclerosis	1.54e-05	0.000131	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—APOA1—atherosclerosis	1.54e-05	0.000131	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—atherosclerosis	1.52e-05	0.000129	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—APOB—atherosclerosis	1.51e-05	0.000128	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP27A1—atherosclerosis	1.5e-05	0.000128	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—BGN—atherosclerosis	1.5e-05	0.000128	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—TGFB1—atherosclerosis	1.5e-05	0.000127	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	1.49e-05	0.000127	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APOA5—atherosclerosis	1.49e-05	0.000126	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—APOB—atherosclerosis	1.47e-05	0.000125	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—atherosclerosis	1.47e-05	0.000125	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—F2—atherosclerosis	1.47e-05	0.000125	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTM1—atherosclerosis	1.46e-05	0.000124	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—AKT1—atherosclerosis	1.45e-05	0.000123	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—AKT1—atherosclerosis	1.45e-05	0.000123	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NOS2—atherosclerosis	1.45e-05	0.000123	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	1.45e-05	0.000123	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—LPL—atherosclerosis	1.44e-05	0.000122	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PLA2G1B—atherosclerosis	1.43e-05	0.000122	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APOA2—atherosclerosis	1.43e-05	0.000121	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALOX15—atherosclerosis	1.43e-05	0.000121	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALOX5AP—atherosclerosis	1.43e-05	0.000121	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PLA2G2A—atherosclerosis	1.43e-05	0.000121	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—PPARA—atherosclerosis	1.42e-05	0.00012	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	1.42e-05	0.00012	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ABCG5—atherosclerosis	1.41e-05	0.00012	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CG—atherosclerosis	1.4e-05	0.000119	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	1.4e-05	0.000119	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GPX1—atherosclerosis	1.4e-05	0.000119	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	1.4e-05	0.000119	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCG8—atherosclerosis	1.4e-05	0.000119	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—LTA4H—atherosclerosis	1.4e-05	0.000119	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ALOX5—atherosclerosis	1.38e-05	0.000117	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atherosclerosis	1.38e-05	0.000117	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CD36—atherosclerosis	1.37e-05	0.000116	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—LPA—atherosclerosis	1.36e-05	0.000115	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—APOA1—atherosclerosis	1.33e-05	0.000113	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—BGN—atherosclerosis	1.32e-05	0.000112	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APOA5—atherosclerosis	1.3e-05	0.000111	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—MTHFR—atherosclerosis	1.29e-05	0.00011	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IGF1—atherosclerosis	1.29e-05	0.000109	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	1.28e-05	0.000109	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PPARA—atherosclerosis	1.27e-05	0.000108	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PLA2G1B—atherosclerosis	1.26e-05	0.000107	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—PPARA—atherosclerosis	1.24e-05	0.000106	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NAMPT—atherosclerosis	1.24e-05	0.000105	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	1.23e-05	0.000105	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—LIPC—atherosclerosis	1.23e-05	0.000105	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—AGT—atherosclerosis	1.23e-05	0.000104	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APOC3—atherosclerosis	1.23e-05	0.000104	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SERPINE1—atherosclerosis	1.22e-05	0.000104	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—LDLR—atherosclerosis	1.22e-05	0.000103	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALOX5—atherosclerosis	1.21e-05	0.000103	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—APOE—atherosclerosis	1.21e-05	0.000102	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CAV1—atherosclerosis	1.19e-05	0.000101	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—APOA1—atherosclerosis	1.19e-05	0.000101	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CETP—atherosclerosis	1.19e-05	0.000101	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—APOA1—atherosclerosis	1.17e-05	9.9e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NOS3—atherosclerosis	1.17e-05	9.9e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SCARB1—atherosclerosis	1.14e-05	9.67e-05	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—AKT1—atherosclerosis	1.12e-05	9.52e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCG1—atherosclerosis	1.11e-05	9.39e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NAMPT—atherosclerosis	1.09e-05	9.23e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CG—atherosclerosis	1.09e-05	9.23e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—LIPC—atherosclerosis	1.08e-05	9.17e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HMGCR—atherosclerosis	1.08e-05	9.13e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APOC3—atherosclerosis	1.07e-05	9.12e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—LDLR—atherosclerosis	1.07e-05	9.06e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PPARG—atherosclerosis	1.05e-05	8.91e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CETP—atherosclerosis	1.04e-05	8.85e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—FABP4—atherosclerosis	1.04e-05	8.83e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—LCAT—atherosclerosis	1.04e-05	8.83e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—AKT1—atherosclerosis	1.04e-05	8.82e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—INS—atherosclerosis	1.03e-05	8.74e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	1.02e-05	8.69e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOA4—atherosclerosis	1.02e-05	8.66e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP7A1—atherosclerosis	1e-05	8.51e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SCARB1—atherosclerosis	9.99e-06	8.48e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	9.71e-06	8.24e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ABCA1—atherosclerosis	9.59e-06	8.14e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ALB—atherosclerosis	9.44e-06	8.01e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HMGCR—atherosclerosis	9.43e-06	8e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP27A1—atherosclerosis	9.27e-06	7.87e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ALB—atherosclerosis	9.24e-06	7.85e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—NOS3—atherosclerosis	9.03e-06	7.66e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOA2—atherosclerosis	8.79e-06	7.46e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	8.79e-06	7.46e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	8.79e-06	7.46e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALOX15—atherosclerosis	8.79e-06	7.46e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCG5—atherosclerosis	8.68e-06	7.37e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ABCA1—atherosclerosis	8.41e-06	7.13e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—VEGFA—atherosclerosis	8.4e-06	7.13e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—LPA—atherosclerosis	8.38e-06	7.11e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTGS2—atherosclerosis	8.26e-06	7.01e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HMOX1—atherosclerosis	8.23e-06	6.99e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—BGN—atherosclerosis	8.12e-06	6.89e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOA5—atherosclerosis	8.04e-06	6.82e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MAPK3—atherosclerosis	7.95e-06	6.74e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APOB—atherosclerosis	7.88e-06	6.69e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	7.74e-06	6.57e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TGFB1—atherosclerosis	7.71e-06	6.54e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTM1—atherosclerosis	7.67e-06	6.51e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—LPL—atherosclerosis	7.53e-06	6.39e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALOX5—atherosclerosis	7.47e-06	6.34e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GPX1—atherosclerosis	7.34e-06	6.23e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HMOX1—atherosclerosis	7.21e-06	6.12e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CD36—atherosclerosis	7.15e-06	6.07e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APOB—atherosclerosis	6.91e-06	5.86e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—MTHFR—atherosclerosis	6.78e-06	5.75e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTM1—atherosclerosis	6.72e-06	5.7e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NAMPT—atherosclerosis	6.7e-06	5.69e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—LIPC—atherosclerosis	6.66e-06	5.65e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPARA—atherosclerosis	6.65e-06	5.64e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOC3—atherosclerosis	6.62e-06	5.62e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—LPL—atherosclerosis	6.6e-06	5.6e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—LDLR—atherosclerosis	6.58e-06	5.58e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—AGT—atherosclerosis	6.44e-06	5.47e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GPX1—atherosclerosis	6.43e-06	5.46e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CETP—atherosclerosis	6.42e-06	5.45e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APOE—atherosclerosis	6.31e-06	5.36e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CD36—atherosclerosis	6.27e-06	5.32e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CAV1—atherosclerosis	6.25e-06	5.31e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APOA1—atherosclerosis	6.24e-06	5.29e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SCARB1—atherosclerosis	6.15e-06	5.22e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—MTHFR—atherosclerosis	5.94e-06	5.04e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPARA—atherosclerosis	5.83e-06	4.94e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HMGCR—atherosclerosis	5.81e-06	4.93e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CG—atherosclerosis	5.69e-06	4.83e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—AGT—atherosclerosis	5.64e-06	4.79e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APOE—atherosclerosis	5.53e-06	4.69e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPARG—atherosclerosis	5.5e-06	4.66e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CAV1—atherosclerosis	5.48e-06	4.65e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APOA1—atherosclerosis	5.47e-06	4.64e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—INS—atherosclerosis	5.39e-06	4.58e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—AKT1—atherosclerosis	5.36e-06	4.55e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCA1—atherosclerosis	5.18e-06	4.4e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CG—atherosclerosis	4.99e-06	4.23e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPARG—atherosclerosis	4.82e-06	4.09e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NOS3—atherosclerosis	4.73e-06	4.01e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—INS—atherosclerosis	4.72e-06	4.01e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HMOX1—atherosclerosis	4.44e-06	3.77e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALB—atherosclerosis	4.33e-06	3.68e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTGS2—atherosclerosis	4.32e-06	3.67e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOB—atherosclerosis	4.26e-06	3.61e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—AKT1—atherosclerosis	4.15e-06	3.52e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NOS3—atherosclerosis	4.14e-06	3.52e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTM1—atherosclerosis	4.14e-06	3.51e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—LPL—atherosclerosis	4.06e-06	3.45e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GPX1—atherosclerosis	3.96e-06	3.36e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CD36—atherosclerosis	3.86e-06	3.28e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTGS2—atherosclerosis	3.79e-06	3.22e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—MTHFR—atherosclerosis	3.66e-06	3.11e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPARA—atherosclerosis	3.59e-06	3.05e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AGT—atherosclerosis	3.48e-06	2.95e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOE—atherosclerosis	3.41e-06	2.89e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CAV1—atherosclerosis	3.37e-06	2.86e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOA1—atherosclerosis	3.37e-06	2.86e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CG—atherosclerosis	3.07e-06	2.61e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPARG—atherosclerosis	2.97e-06	2.52e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—INS—atherosclerosis	2.91e-06	2.47e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALB—atherosclerosis	2.67e-06	2.26e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NOS3—atherosclerosis	2.55e-06	2.17e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTGS2—atherosclerosis	2.33e-06	1.98e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—AKT1—atherosclerosis	2.17e-06	1.84e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—AKT1—atherosclerosis	1.9e-06	1.62e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AKT1—atherosclerosis	1.17e-06	9.96e-06	CbGpPWpGaD
